BIOTRON LIMITED (ASX:BIT) - Broker Meet Biotech August 2018 Dr Michelle Miller Managing Director +61 412 313329 ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
BIOTRON LIMITED
(ASX:BIT)
Broker Meet Biotech
August 2018 Dr Michelle Miller
Managing Director
+61 412 313329
mmiller@biotron.com.au
www.biotron.com.au
Forward Looking Statements This presenta8on may contain forward-looking statements with respect to the financial condi8on, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objec8ves of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “an8cipates”, “es8mates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to iden8fy forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expecta8ons and assump8ons as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assump8ons or expecta8ons could cause actual results to differ materially from current expecta8ons.
Biotron Snapshot
• Clinical stage anPviral drug development company with a promising pipeline of novel drug
candidates targePng serious virus infecPons
• Lead candidate BIT225 is a novel, first-in-class, oral small molecule drug in development for
treatment of HIV-1 and HepaPPs C virus (HCV)
• Posi8ve data in trials to date
• HIV-1 Phase 2 trial complete; data an8cipated end 3Q18
• Provides clinical validaPon of Biotron’s approach to treaPng serious virus infecPons
• Robust pipeline of first-in-class an8viral programs
• Headquartered in Sydney, Australia
• Experienced Board and management team with pharma, financial and VC backgroundsBiotron – AnPviral Focused Pipeline
MECHANISM OF
PROGRAM INDICATION PRECLINICAL PHASE 1/2a PHASE 2 MARKET OPPORTUNITY
ACTION
- ~$20 bn p.a.
Targets HIV-1 Vpu - >36 m living with HIV-1 ww
viroporin protein
HIV-1 Results expected end 3Q18
- 1.1 m in USA
BIT225
- ~$20 bn p.a.
Targets HCV p7 Hepatitis C
Ph 2 complete; seeking partnerships in China - Es8mated 30 – 50 m
viroporin protein virus
infected in China
Targets HCV p7
Hepatitis C
BIT314 viroporin protein
virus
(next generaPon)
- 2.5 bn live in at risk areas
Targets Dengue M
Dengue Dengue - ~100 m infec8ons p.a.
viroporin protein
- No drug treatment
HBV, HBV, - Growing billion dollar
Target specific virus
Respiratory & Respiratory & markets
virporin proteins
others othersBiotron – New Approach to AnP-Viral Drug Development
• Focused on the design and development of a new class of an8viral drugs targe8ng viral-
encoded viroporin proteins
• Viroporins are present in wide range of viruses: Influenza (M2), HIV-1 (Vpu), HCV (p7),
Dengue and West Nile (M protein), SARS (E protein) and others
• Broad planorm:
• Rapid, proprietary primary bacterial cell-based screening assays for target proteins
• Focused library of compounds that target these viral proteins
• Pipeline of internally-generated, first-in-class small molecule viroporin inhibitors
for key marketsHIV-1 EradicaPon HIV-1 remains hidden in reservoirs, leading to chronic, life-long infecPon • Invisible to body’s immune defenses • Not sensi8ve to current an8-HIV-1 drugs • New mode of ac8ons drugs are needed to eradicate or cure HIV-1 infec8on Why is HIV-1 eradicaPon necessary? • Long-term health implica8ons e.g. HAND, immune ac8va8on, drug-drug interac8ons • Compliance/drug holidays can lead to viral rebound • Cost of treatment • ~ $20 billion p.a. world wide • Major burden on healthcare systems
BIT225 Targets HIV-1 in Reservoir Cells
• BIT225 aoacks forma8on of new virus in macrophage reservoirs
• Phase 1b/2a trial (004) demonstrated that BIT225 can reduce HIV-1 levels in macrophage cells in
vivo, paralleling in vitro studies (Wilkinson et al, J An8microb Chemother. 2015)
• Poten8al to add BIT225 to current treatment to clear this source of virus and improve health
A B
(A) Untreated Controls (B) BIT225 treated cellsBIT225-009 Phase 2 HIV-1 Trial
36 HIV-posiJve, treatment-naïve subjects commencing standard anJ-
Subjects
retroviral treatment (ART)
- Double-blind, placebo-controlled, randomised, mulJ-centre study
Protocol - 12 weeks, once daily, oral treatment with BIT225 or placebo in
combinaJon with ART
To determine whether the addiJon of BIT225 impacts on reducJon of virus
Primary Objec3ve
levels over and above ART
Secondary To determine whether BIT225 has any impact on the immune system,
Objec3ve which may indicate addiJonal benefits of the drug in paJents
Clinical component complete; detailed laboratory analyses of paJent
STATUS
samples in progress; data expected 3Q18Investment ProposiPon
• BIT drugs target high growth, mulP-billion dollar markets with defined treatment gaps
• HIV-1 Program - Value inflec8on points around HIV-1 program data expected in late 3Q18
• HCV Program - BIT225 par8cularly well suited to Asia, with high numbers of HCV-infected
pa8ents including a high propor8on of HCV/HBV co-infected pa8ents
• Early stage commercial collabora8on opportuni8es for pre-clinical targets, such as:
• Hepa88s B
• Respiratory viruses
• Seeking partners for individual targets or en8re planormFinancial InformaPon
Key Financial Metrics 12 Month Share Price Performance
Ticker Code ASX: BIT
Share Price (15 Aug ‘18) A $0.017 Ticker Code ASX: BIT
Market cap A $9 million
Share Price (15 Sept 2014) A $0.115
12 Month Trading Range A $0.015 - $0.042
Shares Outstanding 502 million Market cap A $26.3 million
Cash Posi8on (June ‘18) A $1.54 million
12 Month Trading Range A $0.075 – 0.315
Shares Outstanding 228 million
Board
Cash Posi8on (06/14) A $1.76mn
Michael Hoy Non-execu8ve Chairman
Michelle Miller Managing Director
Susan Pond Non-execu8ve Director
Rob Thomas Non-execu8ve DirectorYou can also read
